Clinical Trials

7 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Biliary Tract Neoplasms

NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 Recruiting

400 enrolled

Colonic Neoplasms

NCT07092410 2026-04-21

SuRage-EB

Phase 4 Withdrawn

Melanoma

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

35 enrolled

Melanoma

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

27 enrolled

Phase EARLY_PHASE1 Recruiting

Colorectal Neoplasms

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

50 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Melanoma

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

30 enrolled

Phase EARLY_PHASE1 Active not recruiting

Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled

Phase 2/3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Colonic Neoplasms

NCT06578559 2026-01-05

BRICKET

16 enrolled

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

Brain Neoplasms, Melanoma

NCT06194929 2025-12-03

DETERMINE

Phase 1/2 Recruiting

33 enrolled

Brain Neoplasms, Melanoma

NCT04526782 2025-11-18

ENCO-BRAF

119 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05510895 2025-10-01

NeoBRAF

2 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06887088 2025-10-01

ENCEFALO

33 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Melanoma

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT05706779 2025-09-02

NEORAF

30 enrolled

Colorectal Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

48 enrolled 24 charts

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT06640166 2025-02-12

ECLYPse

25 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT03839342 2025-02-03

BEAVER

26 enrolled

Other solid neoplasm

Solid Tumor

NCT06411600 2024-11-08

BRAVE

94 enrolled

Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

Phase 2 Terminated

5 enrolled 15 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Phase 1/2 Completed

17 enrolled 9 charts

Advanced BRAF Mutant Cancers

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

251 enrolled

Melanoma

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Melanoma

NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Phase 2 Terminated

6 enrolled 16 charts

Pancreatic Neoplasms

NCT04720768 2024-01-05

CELEBRATE

Phase 1/2 Unknown

78 enrolled

Melanoma, Neoplasm Metastasis

NCT02834364 2023-11-24

GMMG-BIRMA

12 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03563729 2023-07-13

MEMBRAINS

80 enrolled

Brain Neoplasms, Melanoma

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Phase 2 Unknown

28 enrolled

Melanoma

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Colorectal Neoplasms

NCT04044430 2023-01-09

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Phase 1 Terminated

2 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

45 enrolled

Melanoma, Neoplasms

NCT02902042 2021-02-16

IMMU-TARGET

Phase 1/2 Completed

16 enrolled

Melanoma

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn